News | November 14, 2025
Novartis opens radioligand therapy facility in Carlsbad, US
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
Subscribe To Our Newsletter & Stay Updated
